Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019

Kherabi, Yousra; Fréchet-Jachym, Mathilde; Rioux, Christophe; Yazdanpanah, Yazdan; Méchaï, Frédéric; Pourcher, Valérie; Robert, Jérôme; Guglielmetti, Lorenzo

doi:10.3201/eid2809.220458

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019

9 2022
By Kherabi, Yousra ; Fréchet-Jachym, Mathilde ; Rioux, Christophe ; ...
http://dx.doi.org/10.3201/eid2809.220458
Source: Emerg Infect Dis. 2022; 28(9):1796-1804

[PDF-604.32 KB]

English

Details Supporting Files You May Also Like

Details:

Alternative Title:

Emerg Infect Dis
Personal Author:

Kherabi, Yousra ; Fréchet-Jachym, Mathilde ; Rioux, Christophe ; Yazdanpanah, Yazdan ; Méchaï, Frédéric ; ... More +

Kherabi, Yousra ; Fréchet-Jachym, Mathilde ; Rioux, Christophe ; Yazdanpanah, Yazdan ; Méchaï, Frédéric ; Pourcher, Valérie ; Robert, Jérôme ; Guglielmetti, Lorenzo Less -
Corporate Authors:

for the MDR-TB Management Group
Description:

Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre-XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are frequently associated with treatment failure and toxicity. We retrospectively determined the effects of pre-XDR/XDR TB resistance on outcomes and safety of MDR TB treatment in France. The study included 298 patients treated for MDR TB at 3 reference centers during 2006-2019. Of those, 205 (68.8%) cases were fluoroquinolone-susceptible MDR TB and 93 (31.2%) were pre-XDR/XDR TB. Compared with fluoroquinolone-susceptible MDR TB, pre-XDR/XDR TB was associated with more cavitary lung lesions and bilateral disease and required longer treatment. Overall, 202 patients (67.8%) had favorable treatment outcomes, with no significant difference between pre-XDR/XDR TB (67.7%) and fluoroquinolone-susceptible MDR TB (67.8%; p = 0.99). Pre-XDR/XDR TB was not associated with higher risk for serious adverse events.
Subjects:

[+]

Antitubercular Agents Extensively Drug-Resistant Tuberculosis Fluoroquinolones Humans Mycobacterium Tuberculosis Retrospective Studies Treatment Outcome Tuberculosis, Multidrug-Resistant
Source:

Emerg Infect Dis. 2022; 28(9):1796-1804
Pubmed ID:

35997386
Pubmed Central ID:

PMC9423894
Document Type:

Journal Article
Place as Subject:

France
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

[+]

urn:sha256:aa314dc2a4b225f61df38f02021ffef3db406bb9d91e0ca0bfa1ba3936ee6348
Download URL:

https://stacks.cdc.gov/view/cdc/121049/cdc_121049_DS1.pdf
File Type:

	22-0458-F.gif	gif
	22-0458-F.jpg	jpeg
	22-0458-Techapp-s1.pdf	pdf
	22-0458.nxml	xml

More +